Loading the section…

COGT: financial statements from SEC — TradeAlmanac

COGT

Cogent Biosciences, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Research and development	75M	69M	62M	63M	64M	54M
Selling, general and administrative	28M	14M	13M	12M	12M	10M
Operating expenses	104M	83M	76M	75M	75M	64M
Operating income	−104M	−83M	−76M	−75M	−75M	−64M
Net income	−97M	−81M	−74M	−72M	−71M	−59M
Earnings per share	−0.53	−0.50	−0.53	−0.52	−0.52	−0.43
Earnings per share, diluted	−0.53	−0.50	−0.53	−0.52	−0.52	−0.43
Weighted average shares	162M	138M	114M	113M	110M	99M
Weighted average shares, diluted	162M	138M	114M	113M	110M	99M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	241M	312M	125M	128M	126M	98M	97M	88M
Current assets	878M	910M	397M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−87M	−67M
Depreciation and amortisation	626,000	640,000
Share-based compensation	17M	10M
Capital expenditure	449,000	547,000
Investing cash flow	−36M	69M
Financing cash flow	53M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator